Email this article Use of nebivolol in patients with mild and moderate hypertensive disease
- Authors: Zhigunova LV1, Lakhova Y.L1, Yurenev AP1
-
Affiliations:
- Issue: Vol 78, No 3 (2003)
- Pages: 59-61
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/29357
- ID: 29357
Cite item
Full Text
Abstract
Aim. To evaluate the effectiveness and safety of the beta-adrenoblocker nebivolol in patients with mild and moderate essential hypertension.
Material and methods. The trial enrolled 20 patients. 11 of them had mild and 9 moderate arterial hypertension (mean age 47.1 ± 9.52years, hypertension history 6.98 ± 2.75years). 2-5 days after discontinuation of hypotensive drugs the examination was made including blood count, ECG, echocardiography, 24-h AP monitoring. It was repeated on days 56-60 of nebivolol therapy. Arterial pressure and heart rate were measured at the start of the treatment and 1, 3, 5 and 8 weeks later.
Results. Nebivolol treatment significantly reduced systolic arterial pressure in 30% and diastolic arterial pressure in 50% patients, heart rate decreased on the treatment day 7-10. On the treatment day 56-60 systolic and diastolic pressure lowered significantly in 53.3% and 66.7% patients, respectively. The analysis of changes in echocardiographic evidence found no significant shifts in volume and linear parameters. Nebivolol was well tolerated by 85% patients. Side effects included head ache, cardialgia, dizziness, weakness and nausea.
Conclusion. Nebivolol (nebilet) is an effective hypotensive drug with mild side effects. Further studies on nebivolol effects on myocardial mass are needed.
Material and methods. The trial enrolled 20 patients. 11 of them had mild and 9 moderate arterial hypertension (mean age 47.1 ± 9.52years, hypertension history 6.98 ± 2.75years). 2-5 days after discontinuation of hypotensive drugs the examination was made including blood count, ECG, echocardiography, 24-h AP monitoring. It was repeated on days 56-60 of nebivolol therapy. Arterial pressure and heart rate were measured at the start of the treatment and 1, 3, 5 and 8 weeks later.
Results. Nebivolol treatment significantly reduced systolic arterial pressure in 30% and diastolic arterial pressure in 50% patients, heart rate decreased on the treatment day 7-10. On the treatment day 56-60 systolic and diastolic pressure lowered significantly in 53.3% and 66.7% patients, respectively. The analysis of changes in echocardiographic evidence found no significant shifts in volume and linear parameters. Nebivolol was well tolerated by 85% patients. Side effects included head ache, cardialgia, dizziness, weakness and nausea.
Conclusion. Nebivolol (nebilet) is an effective hypotensive drug with mild side effects. Further studies on nebivolol effects on myocardial mass are needed.
Keywords
References
- Мазур Н. А. (ред.) Небиволол. Клиническая фармакология и международный
- Cockroft J. R. et al. J. Pharmacol. Exp. Ther. 1995; 274: 1067-1071.
- McLay J. S., Irvine N., McDevitt D. G. Clinical pharmacology of nebivolol. 31, 1991.
- Gao Y., Nagao Т., Bond R. A. ct al. Nebivolol induces endotelium-dependent relaxations of canine arteries. Drug Invest. 1991; 3 (suppl. 1): 118-119.
- Доклад Комитета экспертов ВОЗ. Борьба с артериальной гипертензией. М.;
- Профилактика, диагностика и лечение первичной артериальной гипертонии в Российской Федерации: Первый доклад экспертов Научного о-ва по изучению артериальной гипертонии, Всероссийского научн. о-ва кардиологов и Межведомственного совета по сердечно-сосудистым заболеваниям. 2000.
- Van Bortel L. М. А. В., Joosten J., Breed J. et al. Nebivolol in hypertensive patients. A placebo-controlled multicentre study. Drug Invest. 1991; 3 (suppl. 1): 105-106.
- Van Bortel L. M. А. В., Breed J., Joosten J. et al. Nebivolol in hypertension: a double-blind placebo-controlled multicentre study assessing its antihypertensive efficacy and impact on quality life. J. Cardiovasc. Pharmacol. 1993; 21 (6): 856-862.
Supplementary files
